Allianz Asset Management GmbH cut its holdings in Mylan (NASDAQ:MYL) by 14.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 346,422 shares of the company’s stock after selling 56,423 shares during the quarter. Allianz Asset Management GmbH owned about 0.06% of Mylan worth $10,866,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Canada Pension Plan Investment Board grew its position in shares of Mylan by 99.5% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,217,413 shares of the company’s stock valued at $38,189,000 after purchasing an additional 607,094 shares during the period. FMR LLC grew its position in shares of Mylan by 19.8% in the 2nd quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after purchasing an additional 134,258 shares during the period. Toronto Dominion Bank grew its position in shares of Mylan by 28.2% in the 3rd quarter. Toronto Dominion Bank now owns 200,017 shares of the company’s stock valued at $6,274,000 after purchasing an additional 43,943 shares during the period. Swiss National Bank grew its position in shares of Mylan by 3.1% in the 2nd quarter. Swiss National Bank now owns 1,661,842 shares of the company’s stock valued at $64,513,000 after purchasing an additional 50,100 shares during the period. Finally, Vivaldi Asset Management LLC acquired a new position in shares of Mylan in the 2nd quarter valued at approximately $5,098,000. Institutional investors and hedge funds own 75.04% of the company’s stock.
Shares of Mylan (NASDAQ:MYL) opened at $40.52 on Friday. Mylan has a 12 month low of $29.39 and a 12 month high of $45.87. The stock has a market capitalization of $21,462.81, a P/E ratio of 8.51, a PEG ratio of 2.19 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The company had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the prior year, the company earned $1.38 EPS. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. research analysts forecast that Mylan will post 4.56 earnings per share for the current year.
Several brokerages recently issued reports on MYL. BMO Capital Markets reiterated a “buy” rating and issued a $45.00 price objective on shares of Mylan in a research report on Friday, September 29th. Mizuho reiterated a “buy” rating and issued a $37.00 price objective (down from $53.00) on shares of Mylan in a research report on Sunday, August 20th. Cantor Fitzgerald set a $34.00 price objective on Mylan and gave the company a “hold” rating in a research report on Thursday, November 30th. ValuEngine upgraded Mylan from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Finally, Instinet reiterated a “buy” rating and issued a $37.00 price objective on shares of Mylan in a research report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company. Mylan currently has a consensus rating of “Buy” and a consensus target price of $42.41.
WARNING: This piece was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/16/mylan-myl-shares-sold-by-allianz-asset-management-gmbh.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.